This article is more than 5 years old. Information may no longer be current.
Dermata announces efficacy, safety findings in DMT210 study for treating rosacea
Click Here to Manage Email Alerts
Dermarta Therapeutics, LLC, has announced positive results from a 28-day phase 1 study of its lead compound, DMT210, in treating patients with rosacea.
DMT210 “has minimal systemic exposure, an acceptable safety profile and appears well-tolerated by patients, with most reported local skin reactions as mild,” according to a press release.
Four main clinical endpoints for rosacea were measured, producing meaningful results in efficacy data. These included reducation in lesion counts, investigator global assessment in rosacea, clinician’s assessment of erythema and patient’s severity assessment of erythema. The results indicated that DMT210 may be effective in treating erythema and inflammation and papules and pustules associated with rosacea, according to the release.
“These safety results are supported with eh findings from our pre-clinical data that DMT210 has a favorable safety profile,” Gerald Proehl, president and CEO of Dermata, stated in the release. “We are very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reduction in our 90-day study.”
Phase 2 studies in rosacea and atopic dermatitis are expected to begin later this year, Dermata reported.
Reference: www.demartarx.com